PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1916651
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1916651
According to Stratistics MRC, the Global Gut-Brain Axis & Mood-Enhancing FMCG Market is accounted for $13.43 billion in 2025 and is expected to reach $22.29 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Gut-Brain Axis & Mood-Enhancing FMCG encompasses everyday consumer products that promote emotional and cognitive health by targeting the connection between digestive health and brain function. Such products typically feature functional ingredients like beneficial microbes, plant-based adaptogens, and neuro-supportive nutrients that influence gut microbiota and neural signaling. By integrating mental wellness into routine consumption, these FMCG offerings provide accessible, science-backed options to help manage stress, improve mood, support focus, and enhance overall psychological well-being.
Mainstreaming of psychobiotics
Consumers are increasingly seeking functional foods and beverages that support mental well-being alongside digestive health. Rising stress levels and lifestyle disorders are accelerating demand for mood-enhancing formulations. Scientific validation of probiotics and prebiotics in regulating neurotransmitters is strengthening consumer trust. FMCG companies are investing in R&D to integrate psychobiotics into everyday consumables. Marketing campaigns emphasize holistic wellness, positioning gut health as central to emotional balance. This mainstreaming trend is reshaping product portfolios and expanding adoption across both developed and emerging regions.
High ingredient costs
Specialized strains of probiotics and bioactive compounds require advanced cultivation and preservation techniques. These processes increase manufacturing expenses and limit scalability for smaller firms. High costs also restrict affordability, slowing penetration into price-sensitive markets. Regulatory compliance for safety and efficacy adds further financial burden. Companies must balance innovation with cost efficiency to remain competitive. Without breakthroughs in cost reduction, premium pricing may hinder widespread adoption of mood-enhancing FMCG products.
Hyper-personalization
Consumers are increasingly drawn to tailored nutrition solutions that address individual mood and wellness needs. Advances in microbiome testing and AI-driven analytics enable customized product recommendations. Brands are leveraging digital platforms to deliver personalized subscription models. This trend enhances consumer engagement and loyalty by aligning products with unique health profiles. Hyper-personalization also supports premium positioning, allowing companies to differentiate in a crowded marketplace.
Supply chain volatility
The gut-brain axis FMCG sector is vulnerable to supply chain disruptions due to reliance on specialized ingredients. Strains of probiotics and functional botanicals often require controlled environments and global sourcing. Volatility in logistics, raw material shortages, and geopolitical tensions can delay production. Pandemic-related restrictions highlighted the fragility of ingredient supply chains. Companies are adopting digital monitoring and predictive analytics to mitigate risks. However, persistent volatility threatens inventory stability and timely product launches.
The pandemic reshaped consumer priorities, accelerating demand for mood-enhancing FMCG products. Heightened stress and anxiety during lockdowns boosted interest in psychobiotics and functional beverages. Supply chain disruptions initially constrained availability, creating short-term shortages. However, the crisis also spurred innovation in e-commerce and direct-to-consumer channels. Brands emphasized immunity and mental wellness in marketing, aligning with pandemic-driven health concerns. Regulatory agencies introduced flexible guidelines to support rapid product approvals. Post-pandemic strategies now focus on resilience, digital engagement, and holistic wellness positioning across the FMCG value chain.
The functional beverages segment is expected to be the largest during the forecast period
The functional beverages segment is expected to account for the largest market share during the forecast period. These products offer convenient formats for delivering psychobiotics and mood-enhancing ingredients. Rising consumer preference for ready-to-drink solutions supports segment expansion. Innovations in flavor, packaging, and shelf stability are enhancing appeal. Functional beverages are increasingly marketed as daily wellness routines rather than occasional supplements. Their accessibility across retail and online channels strengthens market penetration.
The stress & anxiety reduction segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the stress & anxiety reduction segment is predicted to witness the highest growth rate. Rising global stress levels are driving demand for targeted mood-enhancing solutions. Psychobiotics and adaptogens are being integrated into FMCG products to address emotional well-being. Scientific evidence supporting their efficacy is boosting consumer confidence. Younger demographics, particularly millennials and Gen Z, are adopting these products for lifestyle management. Digital wellness platforms are amplifying awareness and accessibility.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rising disposable incomes and growing health awareness are fueling demand for functional products. Countries like China, India, and Japan are investing in wellness-focused FMCG innovation. Traditional dietary practices in the region align naturally with probiotic and herbal formulations. Government initiatives promoting local production are strengthening supply chains. Rapid urbanization is increasing exposure to stress, further boosting demand for mood-enhancing consumables.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong R&D investment and technological leadership support rapid innovation in psychobiotics. The U.S. and Canada are pioneering personalized nutrition and microbiome-based solutions. Regulatory frameworks are evolving to streamline approvals for functional ingredients. High consumer awareness of mental health is driving adoption of mood-enhancing FMCG products. Robust e-commerce infrastructure is expanding accessibility and distribution.
Key players in the market
Some of the key players in Gut-Brain Axis & Mood-Enhancing FMCG Market include Nestle S.A., Olipop, Inc., Danone S.A., Seed Health, PepsiCo, Inc., BioGaia AB, Yakult Honsha Co., Ltd., Cargill, Incorporated, Abbott Laboratories, General Mills, Inc., Chr. Hansen Holding A/S, Unilever PLC, Kerry Group plc, BASF SE, and DuPont de Nemours, Inc.
In December 2025, Mars and Cargill, announced they are spurring the development of more than 224MWac* of new renewable energy capacity through five virtual power purchase agreements (PPAs) in Poland. The PPAs were signed with GoldenPeaks Capital, one of Europe's fastest-growing independent producers of renewable energy.
In February 2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd's largest corporate gifts in recent history, a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.